Oct 11 (Reuters) - The U.S. Food and Drug Administration
on Friday agreed to reconsider its recent decision barring drug
compounders from selling their own versions of Eli Lilly's ( LLY )
blockbuster weight loss and diabetes drugs.
The agency said in a court filing it would allow compounding
pharmacies and facilities to continue providing the drugs for
now while it reviews whether there is a shortage of their active
ingredient.